Opendata, web and dolomites

NAFLDcure

A novel pharmaceutical treatment for nonalcoholic fatty liver disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "NAFLDcure" data sheet

The following table provides information about the project.

Coordinator
THE HEBREW UNIVERSITY OF JERUSALEM 

Organization address
address: EDMOND J SAFRA CAMPUS GIVAT RAM
city: JERUSALEM
postcode: 91904
website: www.huji.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) coordinator 150˙000.00

Map

 Project objective

Development of anti-microRNA therapeutic for nonalcoholic fatty liver disease Nonalcoholic fatty liver disease (NAFLD) initiates with excessive accumulation of liver triglycerides and progresses to nonalcoholic steatohepatitis (NASH), cirrhosis and liver cancer while also modifying brain metabolism. However, NAFLD pathogenesis, the corresponding impact on the brain and the links between them, are poorly understood. In addition NAFLD is largely untreatable. We have discovered that excess microRNA (miR)-132 initiates NAFLD and that miR-132 suppression by oligonucleotide antisense treatment effectively reverses NAFLD in acquired and inherited mouse models. Here we to develop this discovery as a novel and effective pharmaceutical for the treatment of NAFLD, a serious and widespread disease for which there is at present no pharmacological treatment.

 Publications

year authors and title journal last update
List of publications.
2018 Geula Hanin, Nadav Yayon, Yonat Tzur, Rotem Haviv, Estelle R Bennett, Shiran Udi, Yoganathan R Krishnamoorthy, Eleni Kotsiliti, Rivka Zangen, Ben Efron, Joseph Tam, Orit Pappo, Eyal Shteyer, Eli Pikarsky, Mathias Heikenwalder, David S Greenberg, Hermona Soreq
miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
published pages: 1124-1134, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2016-312869
Gut 67/6 2019-05-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NAFLDCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NAFLDCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MOCHA (2019)

Understanding and leveraging ‘moments of change’ for pro-environmental behaviour shifts

Read More  

SWIP (2019)

Extended short-wave infrared pulsed fibre laser

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More